Cipla Recalls Lanthanum Carbonate Tablets in US

As per the USFDA, New Jersey-based Cipla USA, Inc is recalling the affected lot due to "complaints received of crushed and broken tablets".

The drug maker initiated the Class II nationwide (US) recall on October 23 this year.

Also Read: Dr Reddy's Labs, FDC recall generic medications in US over manufacturing issues

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

India is the largest supplier of generic medicines with around 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.

The products manufactured in the country are shipped to over 200 countries around the globe, with Japan, Australia, West Europe, and the US as main destinations.